Genotype frequencies of drug-metabolizing enzymes responsible for purine and pyrimidine antagonists in a healthy Asian-Indian population

Biochemical Genetics

Volumn 50, Issue 9-10, 2012, Pages 684-693

  Iyer, Sandhya N ^a   Tilak, Ashwini V ^a   Mukherjee, Manjari S ^a   Singhal, Rekha S ^a  

^a INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

Asian Indians; Cytidine deaminase; Dihydropyrimidine dehydrogenase; Genotyping; India; Pharmacogenomics; Thiopurine S methyltransferase

Indexed keywords

CYTIDINE DEAMINASE; DIHYDROPYRIMIDINE DEHYDROGENASE; DRUG METABOLIZING ENZYME; PURINE ANTAGONIST; PYRIMIDINE ANTAGONIST; THIOPURINE METHYLTRANSFERASE;

ADULT; ALLELE; ARTICLE; ASIAN; CDA GENE; CONTROLLED STUDY; DNA POLYMORPHISM; DPYD GENE; DRUG TOXICITY; FEMALE; GENE FREQUENCY; GENE SEQUENCE; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; INDIAN; MALE; NORMAL HUMAN; POLYMERASE CHAIN REACTION; POPULATION GENETICS; TPMT GENE;

ADOLESCENT; ADULT; ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; CYTIDINE DEAMINASE; DIHYDROURACIL DEHYDROGENASE (NADP); ENZYME ACTIVATION; FEMALE; GENE FREQUENCY; GENETICS, POPULATION; GENOTYPE; GENOTYPING TECHNIQUES; HUMANS; INDIA; MALE; METHYLTRANSFERASES; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PREVALENCE; PURINES; PYRIMIDINES; YOUNG ADULT;

EID: 84866534709     PISSN: 00062928     EISSN: 15734927     Source Type: Journal    
DOI: 10.1007/s10528-012-9511-7     Document Type: Article

References (55)

1. Ameyaw M, Collie-Duguid E, Powrie R, Ofori-Adjei D, McLeod H (1999) Thiopurine methyltransferase alleles in British and Ghanaian populations. Hum Mol Genet 8:367-370 (Pubitemid 29054280)
2. Anglicheau D, Sanquer S, Loriot MA, Beaune P, Thervet E (2002) Thiopurine methyltransferase activity: new conditions for reversed-phase high-performance liquid chromatographic assay without extraction and genotypic-phenotypic correlation. J Chromatogr B Anal Technol Biomed Life Sci 773:119-127 (Pubitemid 34595383)
3. Ashavaid TF, Raghavan R, Shah S, Kapadia A, Almel S, Desai D (2009) TPMT and DPD polymorphisms: efficient screening method for Indian patients considering taking thiopurine and 5-FU drugs. Dis Markers 27:231-238
4. Ben Fredj R, Gross E, Chouchen L, B'Chir F, Ben Ahmed S, Neubauer S, Kiechie M, Saquem S (2007) Mutational spectrum of dihydropyrimidine dehydrogenase gene (DPYD) in the Tunisian population. C R Biol 330:764-769 (Pubitemid 47457228)
5. Canellakis ES (1956) Pyrimidine metabolism: enzymatic pathways of uracil and thymine degradation. J Biol Chem 1:315-322
6. Celik I, Kars A, Guc D, Tekuzman G, Ruacan S (2002) Dihydropyrimidine dehydrogenase enzyme deficiency: clinical and genetic assessment of prevalence in Turkish cancer patients. Cancer Invest 20:333-339 (Pubitemid 34496566)
7. Chabner BA (1996) Cytidine analogues. In: Chabner BA, Longo DL (eds) Cancer chemotherapy and biotherapy. Lippincott-Raven, Philadelphia, pp 213-233
8. Collie-Duguid E, Pritchard S, Powrie R, Sludden J, Collier DA, Li T, McLeod HL (1999) The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics 9:37-42 (Pubitemid 29176722)
9. Dhanya S, Latha R, Jayakumar KL, Ramani T (2011) Comparative study of the toxicity of 5-fluorouraciladriamycin- cyclophosphamide versus adriamycin-cyclophosphamide followed by paclitaxel in carcinoma breast. Ind J Cancer 48:68-73
10. Fukunaga AK, Marsh S, Murry DJ, Hurley TD, McLeod HL (2004) Identification and analysis of singlenucleotide polymorphisms in the gemcitabine pharmacologic pathway. Pharmacogenomics J 4:307-314 (Pubitemid 39341569)
11. Gillman AG, Goodman LS (1985) In Rall TW, Murad F (eds) The pharmacological basis of therapeutics. Macmillan Publishing, New York, pp 1247-1251
12. Grem JL (1996) Fluropyrimidines. In Chabner BA, Longo DL (eds) Cancer chemotherapy and biotherapy. Lippincott-Raven, Philadelphia, pp 149-197
13. Hamdy SI, Hiratsuku M, Narahara K, El-Enany M, Moursi N, Ahmed MS, Mizugaki M (2002) Allele and genotype frequencies of polymorphism cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. Br J Clin Pharmacol 53:596-603 (Pubitemid 34621785)
14. Hamdy SI, Hiratsuka M, Narahara K, Endo N, El-Enamy M, Moursi N, Ahmed MS, Mizugaki M (2003) Genotype and allele frequencies of TPMT, NAT2, GST, SULT1A1 and MDR-1 in the Egyptian population. Br J Clin Pharmacol 55:560-569 (Pubitemid 36783197)
15. Hon YY, Fessing MY, Pui CH, Relling MV, Krynetski EY, Evans WE (1999) Polymorphism of the thiopurine S-methyltransferase gene in African-Americans. Hum Mol Genet 8:371-376 (Pubitemid 29054281)
16. Huang M, Jiang WQ, Lou YL, Cheng MX (2000) Comparison of thiopurine methyltransferase activity between Chinese and Caucasian populations. Chin J Cancer 19:858-861
17. Johnson MR, Wang K, Tillmanns S, Albin N, Diasio RB (1997) Structural organization of the human dihydropyrimidine dehydrogenase gene. Cancer Res 57:1660-1663 (Pubitemid 27199654)
18. Kham SK, Tan PL, Tay AH, Heng CK, Yeoh AE, Quah TC (2002) Thiopurine methyltransferase polymorphisms in a multiracial Asian population and children with acute lymphoblastic leukemia. J Pediatr Hematol Oncol 24:335-336
19. Kham SK, Soh CK, Liu TC, Chan YH, Ariffin H, Tan PL, Yeoh AE (2008) Thiopurine S-methyltransferase activity in three major Asian populations: a population-based study in Singapore. Eur J Clin Pharmacol 64:373-379
20. Krynetski EY, Schuetz JD, Galpin AJ, Pui CH, Relling MV, Evans W (1995) A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci USA 92:949-953
21. Kubota T, Chiba K (2001) Frequencies of thiopurine S-methyltransferase mutant alleles (TPMT*2A, *3B and *3C) in 151 healthy Japanese subjects and inheritance of TPMT*3C in the family of a propositus. Br J Clin Pharmacol 51:475-477 (Pubitemid 32852986)
22. Lee EJ, Kalow W (1993) Thiopurine S-methyltransferase activity in a Chinese population. Clin Pharmacol Ther 54:28-33 (Pubitemid 23227513)
23. McLeod HL, Lin JS, Scott EP, Pui CH, Evans WE (1994) Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharmacol Ther 55:15-20 (Pubitemid 24062187)
24. McLeod H, Pritchard S, Githang'a J, Indalo A, Ameyaw MM, Powrie RH, Booth L, Collie-Duguid ESR (1999) Ethnic differences in thiopurine methyltransferase pharmacogenetics: evidence for allele specificity in Caucasian and Kenyan individuals. Pharmacogenetics 9:773-776 (Pubitemid 30011941)
25. Morel A, Boisdron-Celle M, Fey L, Soulie P, Craipeau MC, Traore S, Gamelin E (2006) Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol Cancer Ther 5:2895-2904 (Pubitemid 44849017)
26. Murugesan R, Vahab SA, Patra S, Rao R, Rao J, Rai P, Gopinath PM, Satyamoorthy K (2010) Thiopurine S-methyltransferase alleles, TPMT*2, *3B and *3C, and genotype frequencies in an Indian population. Exp Ther Med 1:121-127
27. Nakamura T, Saito Y, Murayama N, Saeki M, Soyama A, Sai K, Ozawa S, Sawada J (2001) Apparent low frequency of sequence variability within the proximal promoter region of the cytochrome P450 (CYP) 3A5 gene in established cell lines from Japanese individuals. Biol Pharm Bull 24:954-957 (Pubitemid 32750326)
28. Nauck M, Gierens H, Marz W, Wieland H (2001) Rapid detection of a common dihydropyrimidine dehydrogenase mutation associated with 5-flurouracil toxicity and congenital thymine uraciluria using fluorogenic hybridization probes. Clin Biochem 34:103-105 (Pubitemid 32322700)
29. Nelson DL, Cox MM (2009) Lehninger principles of biochemistry. W. H. Freeman and Co., New York
30. Omura K (2003) Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines. Int J Clin Oncol 8:132-138 (Pubitemid 36897282)
31. Podschun B, Wahler G, Schnackerz KD (1989) Purification and characterization of dihydropyrimidine dehydrogenase from pig liver. Eur J Biochem 185:219-224 (Pubitemid 19262341)
32. Ridge SA, Sludden J, Brown O, Robertson L, Wei X, Sapone A, Fernandez-Salguero PM, Gonzalez FJ, Vreken P, Van Kuilenburg ABP, van Gennip AH, McLeod HL (1998) Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects. Br J Clin Pharmacol 46:151-156 (Pubitemid 28342786)
33. Schroder JK, Kirch C, Seeber S, Schutte J (1998) Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukemia. Br J Haematol 103:1096-1103 (Pubitemid 29012650)
34. Sommadosi JP, Gewritz DA, Diassio RB, Aubert C, Cano JP, Goldman ID (1982) Rapid catabolism of 5-fluorouracil in freshly isolated rat hepatocytes as analyzed by high performance liquid chromatography. J Biol Chem 257:8171-8176
35. Sugiyama E, Kaniwa N, Kim SR, Hanajiri RK, Hasegawa R, Mackawa K, Saito Y, Ozawa S, Sawada J, Kamatani N, Furuse J, Ishii H, Yoshida T, Ueno H, Okusaka T, Saijo N (2007) Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of cytidine deaminase polymorphism. J Clin Oncol 28:32-42 (Pubitemid 350003048)
36. Suzen HS, Yuce N, Guvene G, Duydu Y, Erke T (2005) TYMS and DPYD polymorphisms in a Turkish population. Eur J Clin Pharmacol 61:881-885 (Pubitemid 41803697)
37. Szumlanski C, Otterness D, Her C, Lee D, Brandriff B, Kelsell D, Spurr N, Lennard L, Weiben E, Weinshilboum R (1996) Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol 15:17-30 (Pubitemid 26029354)
38. Tai HL, Krynetski EY, Yates CR, Loennechen T, Fessing M, Krynetskaia NF, Evans WE (1996) Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet 58:694-702 (Pubitemid 26086658)
39. Tai HL, Krynetski EY, Schuetz EG, Yanishevski Y, Evans WE (1997) Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity. Proc Natl Acad Sci USA 94:6444-6449 (Pubitemid 27270704)
40. Ueno H, Kiyosawa K, Kaniwa N (2007) Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy. Br J Cancer 97:145-151 (Pubitemid 47057479)
41. Van Kuilenburg ABP (2004) Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 40:939-950
42. Van Kuilenburg ABP, Vreken P, Abeling NGGM, Bakker HD, Mensma R, Van Lenthe H, De Abreu RA, Smeitink JA, Kayserili H, Apak MY, Christensen E, Holopainen I, Pulkki K, Riva D, Botteon G, Holme E, Tulinius M, Kleijer WJ, Beemr FA, Duram M, Niezen-Koning KE, Smit GP, Jakobs C, Smit LM, van Gennip AH (1999) Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. Hum Genet 104:1-9 (Pubitemid 29134634)
43. Van Kuilenburg ABP, Muller EW, Haasjes J, Meinsma R, Zoetekouw L, Waterham HR, Baas F, Richel DJ, van Gennip AH (2001) Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-flurouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency. Clin Cancer Res 7:1149-1153 (Pubitemid 32708664)
44. Vreken P, Van Kuilenburg ABP, Meinsma R, Smit GPA, Bakker HD, De Abreu RA, van Gennip AH (1996) A point mutation in the invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency. J Inherit Metab Dis 19:645-654 (Pubitemid 26315916)
45. Wei X, McLeod HL, McMurrough J, Gonzalez FJ, Fernandez-Salguero P (1996) Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest 98:610-615 (Pubitemid 26349163)
46. Wei X, Elizondo G, Sapone A, McLeod HL, Raunio H, Fernandez-Salguero PF, Gonzalez FJ (1998) Characterization of the human dihydropyrimidine dehydrogenase gene. Genomics 51:391-400 (Pubitemid 28413205)
47. Weinshilboum R (2001) Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase. Drug Metab Dispos 29(4):601-605 (Pubitemid 32275544)
48. Weinshilboum RM, Sladek SL (1980) Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 32:651-652
49. Yates CR, Krynetski EY, Loennechen T, Fessing MY, Tai HL, Pui CH, Relling MV, Evans WE (1997) Molecular diagnosis of thiopurine s-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 126:608-614 (Pubitemid 27172187)
50. Ye Q, Gu L, Zhao J, Liang A, Ye Y (2000) The study on hereditary polymorphism of thiopurine S-methyltransferasein Chinese Han population of Shanghai area. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 17:421-423
51. Yen JL, Mcleod HL (2007) Should DPD analysis be required prior to prescribing fluoropyrimidines? Eur J Cancer 43:1011-1016 (Pubitemid 46483039)
52. Yonemori K, Ueno H, Okusaka T, Yamamoto N, Ikeda M, Saijo N, Yoshida T, Ishii H, Furuse J, Sugiyama E, Kim SR, Kikura-Hanajiri R, Hasegawa R, Saito Y, Ozawa S, Kaniwa N, Sawada J (2005) Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin. Clin Cancer Res 11:2620-2624 (Pubitemid 40569462)
53. Yue L, Saikawa W, Ota K, Tanaka M, Nishimura R, Uehara T, Maeba H, Ito T, Sasaki T, Koizumi S (2003) A functional single-nucleotide polymorphism in the human cytidine deaminase gene contributing to ara-c sensitivity. Pharmacogenetics 13:29-38 (Pubitemid 36135684)
54. Zhang JP, Guan YY, Wu JH, Xu AL, Zhou S, Huang M (2004) Phenotyping and genotyping study of thiopurine S-methyltransferase in healthy Chinese children: a comparison of Han and Yao ethnic groups. Br J Clin Pharmacol 58:163-168 (Pubitemid 39043996)
55. Zhou S (2006) Clinical pharmacogenomics of thiopurine S-methyltransferase. Curr Clin Pharmacol 1:119-128